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74212 | RSC Adv., 2015, 5, 74212–7421olecular interactions in solid
dispersions using advanced surface chemical
analysis
M. Maniruzzaman,* Martin J. Snowden, Mike S. Bradely and D. Douroumis
The aim of this study is to utilise an advanced surface chemical analysis based on X-ray photoelectron
spectroscopy (XPS) to determine and characterise drug/polymer interactions in solid dispersions
manufactured via hot melt extrusion (HME). Cetirizine HCl (CTZ) and verapamil HCl (VRP) were used as
model cationic drugs while Eudragit® grade L100 and L100-55 polymers were used as anionic carriers. A
molecular dynamics (MD) based simulation approach predicted drug/polymer interactions while
scanning electron microscopy/energy dispersive X-ray spectroscopy (SEM/EDS) mapping showed
homogenous distribution of the drug particles onto the polymer matrices. Hot stage microscopy (HSM)
characterised the solid state of the drugs in extruded formulations. XPS analysis revealed the strength
and nature of interaction between the –NH3 groups of the APIs with the –COOH groups of the polymers.
The results obtained from XPS were supported by XRD and NMR studies. The estimation of non-protonated/
protonated N atom (N/N0) ratios using XPS revealed the strength of the intermolecular interaction in drug/
polymer extrudates which can be used as an eﬃcient tool to study the drug/polymer interaction.Introduction
To date the prediction of drug–polymer interactions is of
exponential interest for the development of solid dispersions
(a mixture of a group of solids consisting of at least two
components). In most instances, solid dispersions consist of a
crystalline drug and an amorphous polymeric carrier (a rela-
tively larger molecule). The process involves the interactions of
a small molecule drug with a polymer matrix. According to the
thermodynamics of mixing, the rst condition for the interac-
tions to take place between a drug in polymer is obtaining
negative change in free energy of mixing.1–4 The change in free
energy of mixing is related to the enthalpy and entropic
contributions according to the following equation (eqn (1)).
DGmix ¼ DHmix  T  DSmix (1)
DGmix is the Gibbs' free energy, whereas DHmix is the
enthalpy of mixing, DSmix is the entropy of mixing and T is the
temperature (system). A negative value of DGmix shows that
the mixing process is spontaneous which decreases upon the
increase ofDSmix in mixing (due to the increase in randomness).
The cohesive and repulsive intra- and intermolecular forces (e.g.
dispersion force, dipole–dipole interaction, and hydrogen
bonding forces) present in the system may also make the drug–
polymer interactions more complicated.ty of Greenwich, Chatham Maritime, Kent
re.ac.uk; D.Douroumis@gre.ac.uk
9The lattice-based Flory–Huggins (F–H) theory, established by
Flory 1952, is a well-known theory describing interactions
between two components based on the Gibbs' free energy
change before and aer mixing.4,5 It has been reported in the
literature that F–H theory can successfully be applied to deter-
mine the strength of the interactions between two compounds
during their melting but to a limited extent.5,6 For example, F–H
theory doesn't work in case of strong multiple interactions the
drug–polymer systems. On the other hand, the available limited
data for diﬀerent group contributions in the van Krevelen
equation for atomic groups also make this approach question-
able.6 This approach also does not take into account the eﬀect of
chain conformation, including branching and linkages between
monomer units and the molecular weight (Mw) of compounds.
These are considered as important factors for the solubility of
the drug molecule into one polymer. Therefore, such limitation
in the foregoingmethods indicates an immense need for amore
robust practical method to accurately determine the interac-
tions in drug/polymer and thus estimate the drug miscibility
with a polymer.
In silico molecular modelling approach based on molecular
dynamics (MD) can be used as a powerful tool to determine the
drug–polymer interactions through both visualization and
estimation of the strength of the interactions. It has been seen
that very few molecular studies in the literature have reported
on MD-based molecular modelling to describe solid dispersion
process as well as drug–polymer interactions.7–16 Recently, the
quantum mechanical (QM) calculations (Gaussian 09) were
used to identify drug/polymer interactions.17,18 The resultsThis journal is © The Royal Society of Chemistry 2015
Fig. 1 (a) Chemical structures of the drugs and polymers, (b) molec-
ular modelling of CTZ with L100 (energy optimized to local minima at
the B3LYP/6-31G* level and veriﬁed by frequency calculations using
Gaussian 09).
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View Article Onlineindicated the existence of hydrogen bonding between the amine
group of the drug molecule and the carboxyl groups of the
polymer among diﬀerent drug/polymer formulations. The X-ray
photoelectron spectroscopy (XPS) can be employed as a valuable
tool for the characterization of polymer surfaces providing a
quantitative elemental analysis and also information on the
chemical bonding within the surface layers of the polymer as
well as the prediction of the changes onto thematerial surface.19
XPS has made a signicant contribution to investigate the 1st
layer atomic surfaces of various polymers providing signi-
cantly precise quantitative elemental analysis and also infor-
mation on the chemical bonding such as H bonding via –NH3
group of the drug (non-protonated/protonated N atom
ratios).18,19 XPS can also provide information about the actual
chemical composition via its advanced surface analysis and
chemical state of surfaces and interfaces determining the
properties of the interacting materials.18 Here we report the rst
case of the non-protonated/protonated nitrogen atoms ratios
(N/N0) determined via advanced chemical surface analysis by
XPS to identify the strength and types of the possible drug–
polymer interactions which has been supported by QM based
molecular modeling. In addition, the EDS based surface anal-
ysis has been used to determine the distribution of the drugs in
solid dispersions while the NMR T1 relaxation time calculation
has successfully elucidated the existence of the intermolecular
interaction between the drugs and polymers.
Materials and method
Materials
Cetirizine HCl (CTZ) and verapamil HCl (VRP) were purchased
from Sigma Aldrich (London, UK). Eudragit L100 (L100) and
Eudragit L100-55 (L100-55) were kindly donated by Evonik
Pharma Polymers (Darmstadt, Germany) and Colorcon Ltd
(Dartford, UK), respectively. All other materials were used as
received. The chemical structures of the compounds used in
this study are given in Fig. 1a.
Hot melt extrusion (HME) processing to manufacture solid
dispersions
Drug/polymer blends were blended in 100 g batches for 10 min
each with a Turbula (TF2, Basel) mixer. The extrusion of all
batches was performed using a Randcastle (USA) single-screw
extruder (RCP0625) equipped with a 5 mm rod die at 100 C/
150 C/155 C/155 C/155 C (feeder / die) temperature
proles and screw speeds at 15 rpm. The drug–polymers
composition consisted of VRP/L100, VRP/L100-55, CTZ/L100
and CTZ/L100-55 at ratios of 10/90 w/w. The produced extru-
dates (strands) were ground by using a Ball Milling System
(Retsch, Germany) to obtain granules (<500 mm) at a rotational
speed of 400 rpm for 5 min.
Flory–Huggins (F–H) interaction parameter (c)
The F–H interaction parameter, c, of the model system was
determined at two diﬀerent conditions using the Nishi–Wang
eqn (2)20This journal is © The Royal Society of Chemistry 20151
Tm
 1
T0m
¼  Rydrug
DHdrugypoly

ln fdrug þ

1 1
mpoly

 1 fdrugþ cdrugpoly1 fdrug2
 (2)
where, y is the molar volume of the repeating unit,m is the degree
of polymerization, f is the volume fraction and c is the crystal-
line–amorphous polymer interaction parameter, Tm and T
0
m is the
crystallinemelting peak of pure drug andmelting peak of the drug
in presence of polymer in the system, respectively. F–H interaction
parameter (c) was also estimated by the method developed by
Hildebrand and Scott according to the following eqn (3).21
c ¼ y

ddrug  dpoly
2
RT
(3)
where, R is the gas constant, T is the absolute temperature, and
y the volume per lattice site and ddrug and dpoly are solubility
parameters of drugs and polymers respectively.Solubility parameter calculated via van Krevelen method
Solubility parameters (d) using van Krevelen methods, of both
drugs as well as the polymers were calculated in order to
determine the theoretical drug/polymer miscibility. ByRSC Adv., 2015, 5, 74212–74219 | 74213
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View Article Onlineconsidering the chemical structural orientations of all drugs/
polymers, the solubility parameters were calculated18 accord-
ing to the following equation:
d ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
dd
2 þ dp2 þ dh2
q
(4)
Here,
dd ¼
P
Fdi
Vi
; dp ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
Fpi
2
q
Vi
; dh ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
Ehi
Vi
s
where d is total solubility parameter, Fdi is the molar attraction
constant due to molar dispersion forces, Fpi
2 is the molar
attraction constant due to molar polarization forces, Ehi is the
hydrogen bonding energy, and Vi the group contribution to
molar volume.Molecular modelling study
The monomeric structures of both polymers and drugs were
constructed by commercially available program Gaussview 09.22
Hydrogen bonding patterns were identied aer energy opti-
misation at the B3LYP 6-31G* level using Gaussian 09.23,24 In all
of the drug/polymers combinations primarily two diﬀerent H
bonding were detected with up to 2 A distance. All possible H
bonding were shown in dash line in the constructed gures.SEM/EDS analysis
Secondary electron images of gold-coated extrudates were
obtained using a Cambridge Instruments Stereoscan scanning
electron microscope at 20 kV. Photomicrographs of pure drugs
and extruded solid dispersions were obtained by a scanning
electron microscopy using a JEOL JSM-5310LV (JEOL, Tokyo,
Japan) at 15 kV accelerating voltage, 20 mm working distance,
spot size 14, secondary electron detector. Elemental assays and
mapping were accomplished using an AZtec Energy Dispersive
X-ray microanalysis system with 50 mm2 X-Max detector (EDS)
(Oxford Instruments). Samples were placed on double sided
adhesive carbon tabs applied to aluminium stubs and coated
with a thin layer of carbon in an Edwards 306 high vacuum
carbon evaporator. All samples were run in singlet.HSM studies
Characterization of drugs in polymeric carrier was assessed
using hot stage microscopy (n ¼ 1). During the analysis, an
Olympus BX60 microscope (Olympus Corp., Centre Valley, PA)
with Insight QE camera (Diagnostic Instruments, Inc., Sterling
Heights, MI) was used to visually observe samples, while a
FP82HT hot stage controlled by a FP 90 central processor
(Mettler Toledo, Columbus, OH) maintained temperatures at
20–250 C. Images were captured under visible and polarized
light using Spot Advance Soware (Diagnostic Instruments,
Inc.).74214 | RSC Adv., 2015, 5, 74212–74219X-ray powder diﬀraction (XRPD)
XRPD was also used to assess the crystalline state of the drug in
all extrudates (n ¼ 1). Samples of pure and loaded drugs were
evaluated using a Bruker D8 Advance (Germany) in theta–theta
mode, Cu anode at 40 kV and 40 mA, parallel beam Goebel
mirror, 0.2 mm exit slit, LynxEye position sensitive detector with
3 degree opening and Lynx Iris at 6.5 mm, sample rotation at
15 rpm. All samples were scanned with a step size of 0.02
degrees 2-theta from 2 to 40 degrees and a counting time of 0.2
seconds per step. All XRPD scans represent a single run.
Nuclear magnetic resonance (NMR) studies
NMR analysis was conducted by using a Jeol ECA 500 NMR
spectrometer, incorporating a 5 mm inverse probe (the 1H
operating frequency was 500 MHz). 1H NMR spectra of the
drugs, polymers and drug/polymer formulations were recorded
using the standard Jeol pulse sequence. All samples were dis-
solved in CD3OD, degassed and then maintained at 25 C
during data acquisition. Samples were referenced with respect
to the solvent. 1H T1 relaxation experiments were recorded for
all samples using a standard inverse recovery experiment.
Recovery delays (s) were investigated between 10 ms and 20 s.
The relaxation delay was set to be >5T1. T1s were calculated from
curve tting (Jeol curve tting soware), peak intensities,
obtained from the spectra recorded for diﬀerent recovery
delays. Samples were run in triplicate.
Advanced chemical surface analysis via XPS
Advanced chemical surface analysis via XPS was performed (n¼
1) by using a Kratos Axis Ultra-DLD using a monochromatic Al
Ka X-ray source (120 W) and an analyzer pass energy of 160 eV
(survey scans) or 20 eV (high resolution scans); the pressure
during analysis was 1  109 Torr. All data were referenced to
the C (1s) signal at 285.0 eV attributable to unsaturated C–C/C–
H bonds.25 Quantication and curve tting was performed in
CasaXPS™ (Version 2.3.15) using elemental sensitivity factors
supplied by the manufacturer.
Results and discussion
F–H interaction and Hansen solubility parameters
The calculation of the interaction parameters by using F–H
theory which depends heavily on various factors such as crys-
talline melting temperature of APIs, Tg of polymers, molecular
volumes and degree of polymerisations has successfully been
implemented in our study. Apparently, the examination of the
molecular structures of both drugs and polymers used in this
study (Fig. 1a) shows that they all are polar and thus can form
additional interactions (e.g. H-bonding). All required data for
the calculation of the interaction parameters were successfully
collected from the thermal analysis of the drug–polymer binary
mixtures.
The negative values of the interaction parameter in Table 1
indicate that there is a net attraction force between species in a
binary mixture.5,6 Therefore higher absolute values of c, suggest
stronger interactions between drug/polymers species. In TableThis journal is © The Royal Society of Chemistry 2015
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View Article Online1, shows that L100 facilitates stronger interactions with both
drugs compared to those of L100-55. To further support this
observation similar results were conrmed by using the Nishi–
Wang approach. However, the overall results obtained from the
F–H calculations just indicate the strength of possible interac-
tions but do not show where the interaction takes place or the
type of interactions. Therefore, a more robust approach using
both molecular modelling and XPS was implemented.
The theoretical approach applied for the estimation of the
solubility parameter suggests that compounds with similar d
values are likely to be miscible. The reason is that the energy of
mixing from intra-molecular interactions is balanced with the
energy of mixing from intermolecular interactions.26 Green-
halgh (1999) demonstrated that compounds with Dd < 7 MPa1/2
were likely to be miscible and compounds with Dd > 10 MPa1/2
were likely to be immiscible.26,27
It has been reported elsewhere28 that the diﬀerence between
the calculated solubility parameters of the polymers and the
drug indicate that both CTZ and VRP are likely to be miscible
with both polymers as the Dd values for CTZ/L100, CTZ/L100-55,
VRP/L100 and VRP/L100-55 are 2.07, 0.97, 3.4 and 2.3 MPa1/2,
respectively. Moreover, the calculated molar attraction constant
due to the hydrogen bonding for both CTZ (9.60 MPa1/2) and
VRP (6.95 MPa1/2) are relatively high and quite close to those
calculated for both polymers (L100: 12.03 MPa1/2 and L100-55,
11.69 MPa1/2). These high H-bonding values from the calcu-
lated solubility parameters may have played a vital role for the
possible drug/polymer intermolecular interactions (see XPS
analysis for more details).Molecular modelling
The dimers of both polymers and the drugs interact predomi-
nantly through hydrogen bonds therefore we interpret the
calculated binding energy (12.0–25.0 kcal mol1) as a reection
of the strength of hydrogen bonds. Overall, the strength of the
interactions is dependent on both the type of donor and
acceptor and the number of hydrogen bonds formed between
the drug and the polymer. Comparisons between VRP/L100 and
between VRP/L100-55 show that with structurally similar poly-
mers L100 and L100-55, the interactions (15.0–25 kcal mol1)
formed between the tertiary amine of the drug and the
protonated carboxylate group of the polymers are signicantly
higher than those (12.0–15.0 kcal mol1) between the alkoxy-
(–O–) group of the drug and the protonated carboxylate group of
the polymers. Similar observations have been seen in case of
CTZ.Table 1 F–H interaction parameter of diﬀerent drug–polymer pairs
Form.
Volume fractions
(f)
Nishi–Wang
(c)
Hildebrand–Scott
(c)  105
VRP/L100 10 : 90 0.25 28.9
VRP/L100-55 10 : 90 0.09 3.70
CTZ/L100 10 : 90 0.21 11.0
CTZ/L100-55 10 : 90 0.08 6.70
This journal is © The Royal Society of Chemistry 2015Higher binding energy represents more stable drug/polymer
intermolecular interactions formed aer the extrusion process.
The interactions between tertiary amine of the drug molecules
(VRP and CTZ) and the carboxylate group of both L100 and
L100-55 (COOH) are the strongest as the intermolecular
distance of two binding sites of drug/polymer is much shorter
(1.3–1.6 A) than the other (Fig. 1b). This simply indicates that
the possible strongest interactions can take place between the
amine group (–NH3) of the drugs and carboxylic group of the
polymers.17,18 However, advanced chemical surface analysis
performed by XPS can validate the ndings from the foregoing
claims.
HME processing to manufacture solid dispersions
Extrusion processing of all CTZ and VRP based formulations
was performed at 155 C with relatively lower screw speed of
15 rpm in order to allow homogenous blending of the drug/
polymer binary mixtures. The rationale for the selection of
high processing temperature was due to the higher Tgs of
polymeric carriers used. Various formulation trials were con-
ducted during the process optimization stage ranging the drug
loading from 10–20% (w/w ratios). Preliminary results showed
no signicant diﬀerences in terms of the solid state of the
extrudates and physical performance between the formulation
containing 20% and 10% drugs. Both CTZ and VRP (cationic
charged substances) were intentionally selected as model drugs
with two diﬀerent polymers (anionic charged) as carriers due to
their oppositively charged groups which can possibly facilitate
intermolecular interactions in order to manufacture molecular
dispersions. The cationic CTZ and VRP may interact with the
functional groups of the negatively charged polymers to eﬀec-
tively develop solid dispersion in HME.
SEM was used to examine the surface morphology of the
drugs and the extrudates. The extrudates containing L100 and
L100-55 showed homogenous particle distribution on the
extruded granules with both VRP and CTZ drugs. Fig. 2 shows
excellent HME processing of the extruded materials where the
particle size distribution (data not shown) showed particle sizes
lower than 500 mm for most formulations ranging from
40–400 mm. Only a small amount of small granules with sizes
<40 mm due to the optimized milling process which reduced
nes in the nal extruded batches.
SEM/EDS analysis
SEM/EDS was performed to determine the presence and
distribution of the drugs in the extruded polymeric matrices.
Chlorine (Cl) atoms were used as a marker to conrm the
presence of both drugs in the extruded polymeric matrices,
because both L100 and L100-55 do not contain Cl atoms in their
structures. The distribution of CTZ and VRP was visualized by
EDS elemental mapping of Cl atoms (Fig. 3a and b). As expected,
the most abundant element detected was carbon, comprising a
majority of APIs and substances for oral drug delivery including
CTZ, VRP and both polymers, which were employed in this
study. Secondary electron images (SEI) showed the sample
morphology, while chlorine Ka X-ray maps and overlays of theRSC Adv., 2015, 5, 74212–74219 | 74215
Fig. 2 SEM images of CTZ pure, CTZ/L100 and VRP/L100-55 extruded
formulations.
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View Article OnlineX-ray maps onto the SEI show the distribution of Cl in the
sample (Fig. 3a and b).
In each formulation, the amount of Cl present in CTZ or VRP
comprised a minimum proportion of all of the other elements.
Oxygen atoms were also detected, and these atoms wereFig. 3 (a) SEM-EDSmapping images of chlorine (Cl) atom detected on
pure CTZ particles. (b) SEM-EDS mapping images of Cl atom detected
on CTZ/L100 extruded formulations.
74216 | RSC Adv., 2015, 5, 74212–74219identied as components of the chemical structure of the drugs
and both polymers.
As can be seen in Fig. 3a that CTZ pure exhibits a homoge-
nous distribution of Cl atoms in EDS mapping indicated by
green color. Since none of the polymeric carriers used in the
extrusion process contain Cl atoms in their chemical structure,
any presence of Cl atoms in the extruded formulations would
have to come from the drug. Fig. 3b indicates that EDSmapping
on the surface of CTZ/L100 extruded formulations conrmed
the presence of Cl atoms. It was also evaluated that CTZ was
homogenously dispersed into the extrudates matrices during
the extrusion processing by EDS mapping analysis. The data
derived from the EDS analysis of CTZ/L100-55 and VRP/
polymers showed quite similar results. A similar study has
been reported by our group recently for the observation of
homogenous distribution of API on extruded tablets.29
HSM analysis
In order to validate the results obtained from DSC reported
previously,28 hot stage microscopy (HSM) studies were con-
ducted to visually determine the live thermal transitions and
extent of drug melting (solubilisation) within the polymer
matrices at diﬀerent stages of heating. Images taken by HSM
under optical and polarizing light are shown in Fig. 4. Both CTZ
and VRP in L100 and L100-55 solid dispersions showed nominal
API melting until reaching temperatures above 140 C and
thereaer from 145 C showed extensive solubilisation of the
drug (Fig. 4). The HSM image taken above 150 C showed
complete solubilisation of both drugs in the inert polymeric
carriers indicating that the drug is miscible with both polymers
used. However, thermal analysis cannot provide further infor-
mation of possible intermolecular interactions patterns.
Therefore, a more advanced chemical surface analysis using
XPS can be of great interest to utilise.
Previous studies28 with diﬀerential scanning calorimetry
(DSC) and X-ray powder diﬀraction showed that both drugs
(CTZ and VRP) were molecularly dispersed within the solid
dispersions.
X-ray powder diﬀraction (XRPD) analysis
X-ray analysis, studied the drug–polymer extrudates, including
pure drugs and physical mixtures (PM) of the same composition
and the diﬀractograms were recorded to examine both APIsFig. 4 HSM images of VRP/L100 and CTZ/L100-55 extruded
formulations.
This journal is © The Royal Society of Chemistry 2015
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View Article Onlinephysical (crystalline or amorphous) state. As depicted in Fig. 5
the diﬀractograms of CTZ and VRP based physical mixtures
presented distinct peaks which are characteristics peaks due to
the presence of crystalline drugs at lower intensities suggesting
that both drugs retained their crystallinity. However, in contrast
no intensity peaks were observed in the extruded formulations.
The absence of crystalline intensity peaks in the extruded
formulations indicates the presence of amorphous APIs in the
extruded solid dispersions complemented by DSC results (data
not shown). This conversion of highly crystalline drugs to its
amorphous forms may also be attributed to the possible inter-
molecular interactions and thus formation of molecular/
amorphous solid dispersions. Similar studies have also been
reported elsewhere to evaluate the drug/polymer interaction.30NMR analysis
1H T1 NMR spectroscopy was employed to monitor the possible
chemical changes and thus the interactions at the molecular
level by analyzing chemical shis of NMR signals. Solid state
NMR was tried initially but the low drug loading in our
formulations didn't accord NMR a meaningful interpretation.
1H T1 NMR experiments were used to analyse spin relaxation
times to look at potential changes of the drug's molecular
motion, before and aer the extrusion process. It would be
assumed that the free drug (with a low molecular weight) would
have quite a high molecular motion leading to fairly high T1
relaxation delays. Aer formulation, any consequence of an
interaction between the drug and polymer would result in a
decrease in the amount of molecular motion observed for the
drug. The calculated T1 relaxation times have signicantly been
decreased in the CTZ/L100 formulations (5445 ms) compared
to that of pure drug (200 ms to 8.2 s) which are equivalent to a
16–20 folds of decrease in the T1 relaxation time. This indicates
the existence of a strong drug/polymer interactions leading to aFig. 5 XRD diﬀractograms of CTZ and VRP loaded physical mixtures
(PM) and extruded formulations (EXT).
This journal is © The Royal Society of Chemistry 2015signicant decrease in the relaxation time. T1 relaxation delays
are particularly sensitive to intermediate molecular motions
and molecules having fast or slow molecular motion can have
comparable T1s.18 Although, the type of interactions cannot be
elucidated by using this NMR analysis but can certainly be used
to indicate the presence of molecular interaction between the
drug and polymer.Advanced surface chemical analysis via XPS
XPS is a powerful technique to analyse the chemical surfaces of
various compounds. The surface chemistry and the diﬀerences
in the total hydrogen consumption between analysed samples
using VRP, CTZ, L100 and L100-55 and their combinations was
revealed via XPS analysis.
Fig. 6 shows that VRP predominantly contained O (22.95%)
and C (76.38%) atoms while CTZ contained O (23.42%) and C
(75.41%). In both drugs N contained less than 1% which is in
good agreement with that of theoretically derived structure
based calculations. The N (1s) binding energy (BE) of both drugs
suggests the protonation of the NH+ group while Cl (2p) energy
of 198.035 eV (data not shown) signicantly supports the
foregoing statement. The N (1s) energy in both drug/polymer
extrudates represents more protonation eﬀects compared to
that of pure drugs. The overall protonation eﬀects in the
extruded formulations can be seen illustrated as the following
equation:
N  H+/ NH3+/NH2+ (5)Fig. 6 XPS surveys of pure CTZ and VRP showing binding energy (BE)
peaks of C 1s, O 1s, N 1s and Cl 2p atoms and their area ratios.
RSC Adv., 2015, 5, 74212–74219 | 74217
Fig. 7 N/N0 ratio determination of VRP in XPS analysis (from the peak
ﬁtting using CasaXPS™ – Version 2.3.15).
Table 2 N/N0 (protonated/non-protonated N atoms) ratios values of
diﬀerent formulations
Formulations
N 1s binding energy (eV)
Calculated N/N0
ratios
Non-protonated
N (eV)
Protonated
N (eV)
CTZ/L100 63.00 100.00 0.63
CTZ/L100-55 85.00 60.00 1.01
VRP/L100 65.00 59.90 0.78
VRP/L100-55 80.00 67.00 1.14
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View Article OnlineThe N (1s) binding energy (BE) of 402.5 eV (Fig. 7) in VRP
suggests the protonation of the NH+ group while the slightly
higher values of N (1s) energy (403.6 eV) in PRP/L100 extrudates
represents further protonation eﬀect of N atom as NH3
+. This
observed N 1s peak at BE¼ 403.6 eV is in good agreement with
the previously observed protonation of amide group by Beamson
and Briggs.31 The BE peak at 403.60 eV (higher than typically
observed for amines BE ¼ 400.5 eV and much more for –NH2+
group) for N 1s is an indication of C–O–NH2
+ structure.32–34
These results strongly indicate an interaction between the
amide group of the API and carboxyl group of the polymer (L100)
viaH-bonding as conrmed by molecular modelling. Similarly, N
1s peaks from VRP/L100-55 also complement the observations
from VRP/L100 formulations. The N (1s) energy of 402.7 eV in
CTZ/L100 formulation suggests protonation of the amide group
as observed for aforementioned VRP/L100 formulation.
The BE peak at 402.7 eV (Fig. 8) for N 1s is an indication of
C–O–NH2
+ structure with slightly lesser peak shi than that of
VRP/L100. As before, it can be concluded that a strong interaction
between the amide group of API and carboxyl group of polymerFig. 8 N/N0 ratio determination of CTZ in XPS analysis (peak ﬁtting
performed using CasaXPS™ – Version 2.3.15).
74218 | RSC Adv., 2015, 5, 74212–74219through H-interactions has taken place.17,35 Furthermore, the
calculations of N/N0 ratio (ratio between non-protonated over
protonated N atoms) for all extruded formulations indicated the
strength of the intermolecular interactions within the solid
dispersions. The calculated N/N0 ratios for all extruded formula-
tions are summarized in Table 2.
The values in Table 2 clearly show that the N/N0 ratios values
of the active L100 extrudates are smaller than those of L100-55
extrudates. It has been reported that the lower the N/N0 ratio,
the higher the amount of protonated N atoms in drugs and thus
the stronger the interaction between polymer and APIs.36,37 So
XPS advanced surface analysis revealed both the strength and
types of the possible intermolecular interactions between each
drugs and polymers used which cannot be done via F–H inter-
action parameter calculations.
Conclusions
The molecular modelling and F–H calculations revealed pres-
ence of intermolecular interactions between drug and polymer
molecules and estimated the strength as well. The ndings
obtained from the surface analysis using EDS mapping showed
the existence of the drug molecule in molecular dispersion
state. The analysis derived from the XRD and NMR studies
revealed the existence of the possible drug/polymer interac-
tions. The ndings from XPS advanced chemical surface anal-
ysis has conrmed the mechanism of the interaction via a
H-bonding between the carboxyl group of the anionic methac-
rylate co-polymers and the amine group of the active substances
as well as the interaction strength. The advanced surface anal-
ysis performed using XPS allows the study of drug–polymer
interactions at the atomic level and with great detail where
traditional methodsmay have signicant limitation to estimate.
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